Xenglu Met XR 12.5mg/1000mg Tablet contains empagliflozin 12.5mg and metformin hydrochloride 1000mg in an extended-release formulation. It is an oral antidiabetic medicine used with diet and exercise to improve blood glucose control in adults with type 2 diabetes.

Empagliflozin belongs to the SGLT2 inhibitor class and helps the kidneys remove excess glucose through urine. Metformin reduces glucose production by the liver and improves the body's sensitivity to insulin. The XR formulation allows metformin to be released gradually.

Uses

• Helps control blood sugar in adults with type 2 diabetes
• Helps increase urinary elimination of excess glucose
• Reduces glucose production by the liver
• Improves insulin sensitivity
• May be prescribed when combination therapy is needed for better glucose control
• Used alongside a healthy diet and regular physical activity

Benefits

• Combines empagliflozin and extended-release metformin in one tablet
• Helps lower elevated blood glucose
• Improves the body's response to insulin
• Helps remove excess glucose through urine
• Extended-release formulation provides gradual metformin release
• Convenient combination treatment

Dosage

• Take Xenglu Met XR 12.5mg/1000mg exactly as prescribed by your doctor.
• It is generally taken once daily with a meal, according to the prescribed regimen.
• Swallow the tablet whole with water.
• Do not crush, chew, or split the XR tablet unless specifically instructed by your doctor or pharmacist.
• Maintain adequate fluid intake unless your doctor has advised fluid restriction.
• Your doctor may monitor blood glucose and kidney function during treatment.
• Do not increase, decrease, or stop the medicine without medical advice.

Possible Side Effects

Some people may experience:

• Nausea
• Diarrhea
• Stomach discomfort
• Increased urination
• Increased thirst
• Urinary tract infections
• Genital fungal infections
• Dehydration or dizziness

Rarely, metformin can cause lactic acidosis, while empagliflozin can cause diabetic ketoacidosis. Seek urgent medical attention for severe weakness, persistent vomiting, abdominal pain, difficulty breathing, confusion, or unusual sleepiness.

Precautions

• Tell your doctor if you have kidney disease, liver disease, heart failure, low blood pressure, recurrent urinary or genital infections, or a history of diabetic ketoacidosis.
• Kidney function should be assessed before and during metformin treatment.
• Maintain adequate hydration unless you have been advised to restrict fluids.
• Inform your doctor before surgery, prolonged fasting, or certain contrast-dye imaging procedures, as treatment may need to be temporarily interrupted.
• Avoid excessive alcohol because it can increase the risk of metformin-associated lactic acidosis.
• The risk of hypoglycemia may increase when Xenglu Met XR is combined with insulin or sulfonylureas.
• Inform your doctor about all medicines, vitamins, and supplements you take.

FAQs

Q1: What is Xenglu Met XR 12.5mg/1000mg Tablet used for?

Xenglu Met XR contains empagliflozin 12.5mg and extended-release metformin 1000mg and is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.

Q2: How does Xenglu Met XR work?

Empagliflozin helps the kidneys remove excess glucose through urine, while metformin reduces glucose production by the liver and improves insulin sensitivity.

Q3: Should Xenglu Met XR be taken with food?

Yes. It is generally taken with a meal to help reduce stomach-related side effects associated with metformin. Follow your doctor's instructions.

Q4: Can Xenglu Met XR be crushed or chewed?

No. Extended-release tablets should generally be swallowed whole. Crushing or chewing may affect how the medicine is released.

Q5: Does Xenglu Met XR cause increased urination?

Yes. Empagliflozin increases glucose and fluid elimination through urine, which can lead to more frequent urination.

Q6: Can Xenglu Met XR cause low blood sugar?

When used alone, the combination has a relatively low risk of hypoglycemia. The risk can increase when it is combined with insulin or sulfonylurea medicines.